Reference:ICH ICH E8 Guideline R1 (2021) 6.2.2: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Gxplex admin (talk | contribs) m 1 revision imported |
||
| (11 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:ICH ICH E8 Guideline R1 (2021) | ||
| | |module=5 | ||
| | |unit=5.4.1 | ||
| | |scope=HM | ||
| | |doc_part=6.2.2 | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
|contributors= | |||
|tags=TAG-00025-Sub-mer ++ TAG-00033-Pro-oto ++ TAG-00287-Sto-pre ++ TAG-00329-Saf-lne | |||
|tags_display=[[Glossary:TAG-00025-Sub-mer|Trial participant]], [[Glossary:TAG-00033-Pro-oto|Protocol]], [[Glossary:TAG-00287-Sto-pre|Stopping rules]], [[Glossary:TAG-00329-Saf-lne|Safety]] | |||
|comment=Withdrawal criteria for individual subjects | |||
|content=6.2.2 Withdrawal Criteria | |||
Clear criteria for stopping treatment or study procedures for a study participant while remaining in the study are necessary to ensure the protection of the participants but should also minimise loss of critical data. | |||
}} | }} | ||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | ICH ICH E8 Guideline R1 (2021) |
| Validity area | ICH |
| Scope(s) | HM |
| Document name | ICH E8 Guideline |
| Version / Revision | R1 (2021) |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | ICH guideline E8 (R1) on general considerations for clinical studies |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 — Unit 5.4.1 |
| Scope | HM |
| Document part | 6.2.2 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Trial participant, Protocol, Stopping rules, Safety |
Content
6.2.2 Withdrawal Criteria Clear criteria for stopping treatment or study procedures for a study participant while remaining in the study are necessary to ensure the protection of the participants but should also minimise loss of critical data.
